Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 2, 2020
Daily News
September 2, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
- AMED to Fund 7 More Company-Led COVID-19 Vaccine Projects Including Takeda, Daiichi Sankyo
September 2, 2020
- Gilead Revises Veklury Label Warning of Coadministration with Hydroxychloroquine or Chloroquine
September 2, 2020
- Taisho, Takeda to Wind Up Japan Distribution Deal for Biofermin’s Prescription Drugs
September 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…